Multifocal, EDOF, and Light Adjustable IOLs in Glaucoma

In this AGS 2024 interview with Dr. Arsham Sheybani, Dr. Paul Harasymowycz provides an overview of his talk about multifocal, extended depth of focus (EDOF), and light adjustable IOLs for patients with glaucoma. He discusses several considerations, including the amount of ocular surface disease, the size of the patient's pupil, and whether there is angle closure. Clinicians must also take into account that different lenses involve varying amounts of lost light—which can be of special concern for patients with more advanced glaucoma—and that all lenses have some level of side effects (e.g., haloes, glistening) that are often exacerbated by glaucoma. In many cases, family history may provide some insight into how advanced glaucoma could become, allowing for more accurate IOL recommendations.

Financial Disclosures: Dr. Arsham Sheybani discloses financial relationships with Alcon Laboratories, Allergan, Elios, Glaukos, and Nova Eye Medical (Consultant/Advisor). Dr. Paul Harasymowycz discloses financial relationships with Abbvie, Alcon, Bausch + Lomb, Bayer Healthcare Pharmaceuticals, Glaukos, Johnson & Johnson, Novartis Pharmaceuticals AG, and THEA (Consultant/Advisor, Lecture Fees/Speakers Bureau).